Thalidomide and its derivatives: emerging from the wilderness

J N Gordon, P M Goggin

Forty years on from its worldwide withdrawal, thalidomide is currently undergoing a remarkable renaissance as a novel and powerful immunomodulatory agent. Over the last decade it has been found to be active in a wide variety of inflammatory and malignant disorders where conventional therapies have failed. Recently, considerable progress has been made in elucidating its complex mechanisms of action, which include both anticytokine and antiangiogenic properties. However, in addition to its well known teratogenic potential, it has a significant side effect profile that leads to cessation of treatment in up to 30% of subjects. In response to this, two new classes of potentially safer and non-teratogenic derivatives have recently been developed. This review summarises the biological effects, therapeutic applications, safety profile, and future potential of thalidomide and its derivatives.

Thalidomide was first introduced in West Germany in 1956 and in the rest of Europe, Australia, Canada, and South Africa in 1957. Fortuitously, its release in the United States was delayed by the Food and Drug Administration pending clarification of concerns regarding the results of neurotoxicological studies in animals. It was initially marketed as a sedative, with its rapid speed of onset, lack of hangover effect, and apparent safety after overdose making it an attractive alternative to barbiturates. In addition it was a powerful antiemetic, and was widely taken by pregnant women for the treatment of morning sickness. However, soon after its release, there followed a rapid rise in reported cases of a previously rare birth defect, phocomelia (congenital limb foreshortening). In 1961, after reports linking this to in utero thalidomide exposure, the drug was withdrawn leaving a legacy of between 6000 and 10 000 affected children.1

However, a few years later, the serendipitous discovery of thalidomide’s anti-inflammatory potential ensured it was never entirely forgotten. In the course of treating a patient with mania and leprosy, Sheskin, an Israeli physician, administered some old supplies of thalidomide for its sedative effect. This resulted in the dramatic and virtually complete resolution of the patient’s cutaneous symptoms, and was the first indication of the drug’s potential.1 However, it was not until the discovery of thalidomide’s antitumour necrosis factor-α (TNF-α) activity in 1991 that interest really intensified.1 Since then, a significant body of work has now been published that has helped to gradually elucidate the mode of action, and potential uses of this unique drug.

PHARMACOKINETICS

Thalidomide, a derivative of glutamic acid, is administered clinically as a 1:1 racemic mixture of its S and R isomers. It is well absorbed after oral administration with maximal plasma levels of around 1–4 µg/ml reached within 2–4 hours. There is some evidence to suggest that individual isomers have different biological properties with the S-isomer responsible for the immunomodulatory effects, while the R-isomer accounts for the sedative effect.4 In animal studies, both isomers caused fetal malformations when administered to the New Zealand rabbit (a species known to be sensitive to its teratogenic effects), whereas in rodents (a less sensitive species), malformations were only observed in those who received the S-isomer.9 However, in humans, the rapid chiral interconversion that occurs between the two isomers in vivo limits any potential benefit from administering a specific isomer. Thalidomide is eliminated by pH dependant spontaneous hydrolysis to multiple chemically inactive metabolites, and has a half life of approximately five hours. As there is virtually no excretion via the liver or renal pathways the risk of drug interactions is low. Specifically, it has been shown that thalidomide does not affect the metabolism of oral contraceptive pills containing norethindrone or ethinyl oestradiol.10 Thalidomide has recently been shown to be present in the semen after oral dosing.11

The structure of thalidomide is shown in fig 1.

Figure 1 Structure of thalidomide.

Abbreviations: GvHD, graft versus host disease; IFN-γ, interferon-γ; IL, interleukin; TNF-α, tumour necrosis factor-α
**IMMUNOLOGICAL PROPERTIES**

Thalidomide's immunomodulatory properties are complex and incompletely understood. Multiple mechanisms of action have been reported, with the best recognised being its ability to inhibit the production of TNF-α.

In contrast with corticosteroids thalidomide can inhibit monocyte derived TNF-α production without down-regulating interleukin (IL)-1β, IL-2, or IL-6 production.\(^1\)\(^2\) Though initially thought to primarily act only on monocytes, thalidomide has since been shown to down-regulate TNF-α production across a broad range of cell types including T-lymphocytes, alveolar macrophages, lamina propria mononuclear cells, and microglial cells.\(^3\)\(^4\) Maximal inhibition is in the order of approximately 50%–70% with some variation between cell types.\(^5\) The mechanism by which thalidomide suppresses TNF-α production remains unclear. It appears to interfere with gene transcription or translation, and has been demonstrated to enhance TNF-α mRNA degradation.\(^6\) More recently it has been shown to inhibit NF-kappaB activation, a ubiquitous transcription factor that promotes the production of inflammatory cytokines, through suppressing I-kappaB kinase activity.\(^7\)\(^8\) Finally, there is also some evidence that in certain circumstances thalidomide may be able to augment TNF-α production, potentially indicating cell specific effects.\(^9\)\(^10\)

In addition to its effects on TNF-α production thalidomide can influence other cytokine production. Concurrently with suppressing TNF-α production, thalidomide has been shown to simultaneously enhance production of IL-4 and IL-5, in effect promoting a shift from a Th1 to Th2 cytokine pattern.\(^11\)\(^12\) Additionally, thalidomide has been shown to have a bidirectional effect on IL-12 production, a cytokine that is central to the development of an effective cellular immune response.\(^13\) Thalidomide suppresses IL-12 production by mitogen activated monocytes and lamina propria cells, while it enhances production when stimulated through the T-cell receptor.\(^14\)\(^15\)\(^16\) These dichotomous results may in part be explained by the recently recognised ability of thalidomide to act as a T-cell co-stimulant under certain circumstances. The addition of thalidomide to cultures of T-cells activated through the T-cell co-stimulant under certain circumstances. The addition of thalidomide to cultures of T-cells activated through the T-cell receptor, results in an enhanced Th1 response with augmented production of IL-2 and interferon-γ (IFN-γ) along with an increase in cell proliferation.\(^17\) This is of interest as the ability to provoke a marked Th1 response is potentially beneficial in enhancing antitumour activity. In one recent study, CC-4047, a thalidomide derivative with marked co-stimulatory activity, was able to prime protective, long lasting, tumour specific responses in a mouse model.\(^18\)\(^19\)\(^20\)\(^21\)

Finally, a further potentially important property of thalidomide is its antiangiogenic effects. In vitro studies have shown thalidomide to be capable of inhibiting angiogenesis induced by vascular endothelial derived growth factor and basic fibroblast growth factor.\(^22\)\(^23\) A subsequent study has also shown this effect to be independent of TNF-α suppression.\(^24\)

**THALIDOMIDE DERIVATIVES**

Over the last few years the re-emergence of thalidomide has awakened interest in developing structural analogues that possess its immunomodulatory properties without the associated side effects. Several such compounds have recently been developed that are up to 50 000-fold more potent than thalidomide at inhibiting TNF-α on a molar basis.\(^25\) They are broadly split into two main groups, dependent on their biological effects. The first class, immunomodulatory drugs, strongly inhibit TNF-α along with IL-1β, IL-6, and IL-12 while augmenting IL-10 production. They are also potent co-stimulators of T-cells when activated through the T-cell receptor and dramatically increase T-cell proliferation. They do not inhibit phosphodiesterase-4. The second class, selective cytokine inhibitory drugs, again potently inhibit TNF-α, though much more selectively, having considerably less effect on other inflammatory cytokines. They have little effect on T-cell activation, causing only a slight inhibition in T-cell proliferation. These compounds do markedly inhibit phosphodiesterase-4, though it is currently unclear how much this contributes to their biological effects.\(^26\)\(^27\)

Importantly, preliminary results from animal studies have shown at least some of these compounds to be clinically effective, and non-toxic and non-mutagenic.\(^28\)\(^29\) Several are now undergoing phase I and phase II clinical trials though none are currently in routine clinical use.

**CLINICAL APPLICATIONS**

**Leprosy**

Erythema nodosum leprosum is an acute vasculitis seen in patients with lepromatous leprosy after antilepromatous treatment. It is characterised by a painful, ulcerative, nodular rash and systemic symptom such as fever, arthralgia, neuritis, and glomerulonephritis. Immunologically, it involves components of both a cell mediated immune response and an immune complex mediated disease. Subsequent to Sheskin's original discovery several controlled and uncontrolled studies, including a World Health Organisation coordinated randomised controlled trial, have been published confirming its effectiveness.\(^30\) More recently a literature review by Sheskin in 1980 analysed data from 4552 cases and found the response rate to treatment to be 99%. Its effectiveness is thought to be due to its anticytokine effects with responders showing a marked reduction in serum TNF-α, IFN-γ, TNF-α, and IL-12, and an immune complex mediated disease. Subsequent to Sheskin's original discovery several controlled and uncontrolled studies, including a World Health Organisation coordinated randomised controlled trial, have been published confirming its effectiveness.\(^31\)\(^32\)\(^33\) Its effectiveness is thought to be due to its anticytokine effects with responders showing a marked reduction in serum TNF-α, IFN-γ, TNF-α, and IL-12, and an immune complex mediated disease. Subsequent to Sheskin's original discovery several controlled and uncontrolled studies, including a World Health Organisation coordinated randomised controlled trial, have been published confirming its effectiveness.\(^31\)\(^32\)\(^33\)

**Mucocutaneous ulceration**

Thalidomide has proved to be highly effective in the treatment of both resistant oral aphthous ulceration, and HIV associated aphthous ulceration. In a placebo controlled crossover trial in patients with severe oral ulceration, 42% went into complete remission with active treatment compared with 8% on placebo.\(^34\) Similarly, in trials involving HIV associated ulceration, 53% with oral and 73% with oesophageal ulceration went into complete remission compared with 8% and 23% in the respective placebo groups.\(^35\)\(^36\)

In Behçet's disease several uncontrolled studies have all shown thalidomide to be effective in both treatment, and prevention of recurrence of orogenital ulceration.\(^37\) However in the only placebo controlled trial, complete response rates of 9% on treatment over 0% on placebo, while statistically significant, were not particularly impressive.\(^38\)
Irrespective of aetiology, mucocutaneous ulceration often recurs after cessation of therapy, necessitating recurrent courses of treatment.

**Crohn’s disease**

Thalidomide’s potential as a treatment for inflammatory bowel disease was first reported in 1979 after its successful use in a patient with severe unresponsive ulcerative colitis. However, it is only recently, after the discovery of the central role of TNF-α in the pathogenesis of Crohn’s disease, that attention has returned to it. In 1999 two papers were published simultaneously, in which patients with steroid resistant or steroid refractory Crohn’s disease were successfully treated with oral thalidomide for a total of 12 weeks. Subsequently, two other open label trials have now been published. In total in the four trials 49 patients have been treated. Overall 85% of patients who completed the trials responded to treatment, though a relatively high number, 27%, withdrew due to the development of adverse events. Preliminary reports also indicate thalidomide to be effective as maintenance treatment after induction of remission with infliximab.

**Wasting and cancer cachexia**

Anorexia and cachexia associated with chronic illness is known to be in part mediated through a Th1 immune response with enhanced production of proinflammatory cytokines such as TNF-α, IL-1β, and IL-6. It is associated with a shortened life expectancy in cancer sufferers. Thalidomide has been shown to be able to retard or reverse this weight loss in a number of conditions. Randomised controlled trials have confirmed its efficacy in reversing weight loss in patients with HIV associated wasting and in patients with active pulmonary tuberculosis. Encouraging results have been also been published in a pilot study of patients with cachexia associated with advanced oesophageal malignancy. However, to date no randomised controlled trials have yet been reported. Finally, in several uncontrolled preliminary studies the combination of thalidomide’s antiemetic, analgesic, and sedative effects have been effective in the palliation of patients with terminal malignancy and otherwise intractable symptoms.

**Haematological malignancies**

Angiogenesis is important in the progression of haematological malignancies such as leukaemia, lymphoma, myelodysplasia, and myeloma. In view of this there has been considerable interest in the use of drugs such as thalidomide that possess immunomodulatory and antiangiogenic properties. The most promising results to date have been in the treatment of multiple myeloma. In 1999 Singhal et al reported a 32% response rate in 84 patients with high risk refractory myeloma treated with thalidomide. Several further studies have now confirmed these findings with published response rates of 25%–35% with responders showing a decrease in plasma and bone marrow levels of basic fibroblast growth factor, vascular endothelial derived growth factor, and TNF-α. Polymorphisms of the TNF-α gene promoter correlate with pretreatment serum TNF-α levels, and appear able to predict outcome with high producers more likely to respond to therapy.

Thalidomide should now be recommended as standard treatment for patients with advanced refractory multiple myeloma. Furthermore, encouraging results have also been obtained in Phase I/II pilot studies using the immunomodulatory drugs, though no peer reviewed papers have been published to date. Thalidomide may also be effective in the treatment of high risk myelodysplasia, acute and chronic myeloid leukaemia, and other myeloproliferative disorders. In the largest published trial including 83 patients with refractory anaemia secondary to myelodysplasia 31% of those completing treatment responded with 20% becoming independent of transfusions.

**Solid organ malignancies**

Responses have been seen in up to a third of patients with Kaposi’s sarcoma, and in some patients with renal cell carcinoma, and high grade glioma, though in recent studies it was of little benefit in patients with advanced breast cancer and advanced melanoma. In combination therapy with thiotepa for advanced colorectal cancer, it eliminated the side effects of chemotherapy allowing patients to complete treatment. However there have recently been several reports of a high incidence of thromboembolic disease in patients with advanced cancer treated with thalidomide. Consequently, though it does appear to possess some activity against solid tumours the risk/benefit ratio as a single agent is marginal and it cannot currently be recommended. Further studies are currently underway to assess its potential in combination therapy.

**Dermatological conditions**

Thalidomide has proved to be an effective antipruritic agent in a number of dermatological disorders. It has been used successfully in the treatment of uraemic pruritus in patients undergoing haemodialysis, and in the treatment of prurigo nodularis which is associated with intense itching. It has also been used successfully in the treatment of a number of other dermatological conditions resistant to conventional therapies including porphyria cutanea tarda, discoid lupus, acyclic prurigo, cutaneous histiocytosis X, and pyoderma gangrenosum.

On the basis of its anti-TNF-α activity thalidomide was also administered in a randomised placebo controlled trial to patients with toxic epidermal necrolysis, a dramatic, life threatening condition with a 30% mortality. Though only small numbers were involved, the trial was stopped early due to an excess of deaths in thalidomide arm (p=0.007). The authors speculate this may have been due to a paradoxical enhancement of TNF-α production.

**Graft versus host disease (GvHD)**

Chronic GvHD occurs in up to 40% of patients after allogeneic bone marrow transplant. It is characterised by a sicca-like syndrome that predominantly affects the skin, gastrointestinal tract, liver, and immune system. Animal studies using a rat major histocompatibility complex mismatch model have shown thalidomide to be effective in both the prophylaxis and treatment of GvHD. Subsequent clinical studies using thalidomide for refractory chronic GvHD have given encouraging results, with response rates in the region of 38% to 59%. However, a more recent randomised controlled trial failed to show any clear benefit from the addition of thalidomide over and above that of conventional immunosuppressive therapy.

**Rheumatological disorders**

Results from animal studies indicate that thalidomide and its derivatives are effective in inhibiting the development of arthritis in specific mouse models. However after an initial enthusiastic report where 12 out of 17 patients with refractory arthritis responded to treatment, results from more recent clinical studies have shown little or no benefit.

There have been several small case series of patients with refractory sarcoidosis, scleroderma, and cutaneous lupus who responded to thalidomide. However no convincing large case series or randomised controlled trials have yet been published, and currently there is not enough reliable evidence to report efficacy.

Conditions for which thalidomide has shown potential are shown in box 2.

**TERATOGENICITY**

Thalidomide is well known to be extremely teratogenic. The effects are species dependent as seen from animal studies
where the New Zealand rabbit fetus develops typical abnormalities after exposure, while the rat fetus remains largely unaffected. In humans it has been estimated there is a 10%–50% risk of subsequent birth defects after in utero exposure, with even a single 50 mg dose capable of causing severe abnormalities if administered during the first trimester of pregnancy. The most frequent fetal abnormalities seen in humans are phocomelia (short limbs) or amelia (absent limbs). Other common abnormalities include central skeletal abnormalities, malformation of internal organs, and craniofacial abnormalities. The term mortality rate in affected cases is reported to be around 40%, mostly in relation to failure of major organ formation.

The specific mechanism or mechanisms responsible for thalidomide’s teratogenicity are currently unknown. In one study thalidomide has been shown to cause free radical mediated oxidative damage to embryonic cellular DNA in rabbits, while in another it appears to interact with the adhesion molecule N-cadherin, disturbing cellular recognition and migration during embryogenesis. It has also been proposed that thalidomide may, by binding to specific promoter sites, inhibit the transcription of genes involved in normal developmental angiogenesis.

OTHER SIDE EFFECTS
Peripheral neuropathy is the most serious side effect to occur with a reported incidence of anywhere from 1% to 70% dependent on definition and the underlying disorder. A recent large prospective study reported an incidence of 10% with age and cumulative dose being contributory factors, though another retrospective study did not find a link with either daily or cumulative dose. It characteristically presents as a painful or burning sensory neuropathy in association with mild proximal muscle weakness. Weakness rapidly resolves after cessation of therapy, though sensory changes are typically slow to recover and in some cases may be irreversible. The predominant underlying pathological lesion is axonal degeneration.

Other recognised side effects of thalidomide include drowsiness, macular rash, constipation, dizziness, decreased libido, mild endocrine effects, and rarely neutropenia (see box 3).

PRECAUTIONS FOR USE
In view of the serious risk of teratogenicity the worldwide availability of thalidomide is extremely limited. In the United States it is only commercially available through the manufacturer regulated System for Thalidomide Education and Prescribing Safety (STEPS) programme. In the UK it is available on a named patient basis in accordance with section 5(1) of the Medicines Act 1968.

It should only be used for the treatment of severe disabling conditions causing unacceptable interference with normal life, when other treatments have been tried and failed. Patients should sign a consent form before starting treatment, and specific detailed contraceptive precautions must be adhered to. Patients should undergo regular clinical examination while on treatment and be advised to stop treatment if they develop neuropathic symptoms. Baseline nerve conduction studies may be useful before initiating therapy. Excessive daytime somnolence can be minimised by bedtime dosing, and usually resolves over the first few weeks of therapy. Anyone involved in prescribing thalidomide should refer to the published guidelines on the clinical use and dispensing of the drug in the UK for more detailed information.

Precautions for the prevention of pregnancy are shown in box 4.

CONCLUSION
Despite its inherent dangers, thalidomide clearly represents an important therapeutic option in selected patients. Its most
Box 4: Precautions for the prevention of pregnancy

During treatment any women of childbearing potential* must:

• Be made aware of the risk of birth defects and other serious side effects associated with thalidomide.
• Complete a written consent form.
• Provide a negative pregnancy test within one week before starting thalidomide, and undergo regular pregnancy testing while on treatment.
• Agree to abstain from intercourse or use two forms of contraception at the same time, which must begin one month before starting thalidomide and continued for at least one month after stopping treatment.

(A) Sterilisation *(male or female)* is not 100% reliable and as such an additional method of contraception must be used.

(B) Women who do not normally practice contraception because of a history of infertility should do while taking thalidomide.

• Male patients must be instructed to use a condom every time they have intercourse even if they have undergone vasectomy.
• No more than one month’s supply of thalidomide should be prescribed at any given time.

*A woman of childbearing potential is defined as any woman under the age of 54 or over, who is still having natural periods or is menstruating.*

Authors’ affiliations
J N Gordon, Division of Infection, Inflammation, and Repair, University of Southampton, Southampton General Hospital, Southampton
P M Goggin, Department of Gastroenterology, Queen Alexandria Hospital, Portsmouth

REFERENCES
chronically active and fistulizing refractory Crohn’s disease. Pharmacol Ther
efficacy of thalidomide for symptomatic inflammatory bowel disease. AIDS
AIDS associated wasting. 55.
–2002;77:813–22.
alpha gene promoter predict for outcome after myeloma.
Thalidomide and its derivatives: emerging from the wilderness

J N Gordon and P M Goggin

doi: 10.1136/pmj.79.929.127

Updated information and services can be found at:
http://pmj.bmj.com/content/79/929/127

These include:

References
This article cites 75 articles, 16 of which you can access for free at:
http://pmj.bmj.com/content/79/929/127#Bibl

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/